Zacks: Brokerages Expect Eiger Biopharmaceuticals Inc (EIGR) to Announce -$0.82 EPS
Wall Street analysts predict that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will announce ($0.82) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eiger Biopharmaceuticals’ earnings. The lowest EPS estimate is ($1.13) and the highest is ($0.60). Eiger Biopharmaceuticals reported earnings of ($1.10) per share during the same quarter last year, which indicates a positive year over year growth rate of 25.5%. The firm is scheduled to report its next earnings report on Thursday, November 8th.
On average, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($3.19) per share for the current financial year, with EPS estimates ranging from ($4.22) to ($2.71). For the next financial year, analysts forecast that the firm will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.82) to ($2.60). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Eiger Biopharmaceuticals.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.82) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.82).
Several institutional investors and hedge funds have recently bought and sold shares of EIGR. Jennison Associates LLC raised its stake in shares of Eiger Biopharmaceuticals by 93.3% during the 2nd quarter. Jennison Associates LLC now owns 1,256,501 shares of the biotechnology company’s stock worth $15,329,000 after purchasing an additional 606,361 shares in the last quarter. GMT Capital Corp purchased a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $3,459,000. BlackRock Inc. raised its stake in shares of Eiger Biopharmaceuticals by 171.0% during the 2nd quarter. BlackRock Inc. now owns 219,278 shares of the biotechnology company’s stock worth $2,675,000 after purchasing an additional 138,366 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Eiger Biopharmaceuticals during the 2nd quarter worth about $871,000. Finally, Renaissance Technologies LLC raised its stake in shares of Eiger Biopharmaceuticals by 40.4% during the 2nd quarter. Renaissance Technologies LLC now owns 230,229 shares of the biotechnology company’s stock worth $2,809,000 after purchasing an additional 66,200 shares in the last quarter. 71.61% of the stock is owned by institutional investors.
Shares of NASDAQ EIGR opened at $11.85 on Wednesday. Eiger Biopharmaceuticals has a one year low of $7.46 and a one year high of $18.00. The stock has a market cap of $101.18 million, a price-to-earnings ratio of -2.44 and a beta of 1.68. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.51 and a quick ratio of 4.51.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Story: Closed-End Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.